- Home
- MNOV vs DXR Comparison
MNOV vs DXR Comparison
Compare MNOV & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | DXR |
|---|---|---|
| Founded | 2000 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.4M | 59.0M |
| IPO Year | 2004 | 1995 |
Fundamental Metrics
Financial Performance| Metric | MNOV | DXR |
|---|---|---|
| Price | $1.28 | $10.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 41.5K | 2.2K |
| Earning Date | 05-14-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,360,807.00 | $1,446,345.00 |
| Revenue This Year | N/A | $44,935.22 |
| Revenue Next Year | $180.00 | $74.79 |
| P/E Ratio | ★ N/A | $33.83 |
| Revenue Growth | ★ 194.15 | N/A |
| 52 Week Low | $1.17 | $8.56 |
| 52 Week High | $1.96 | $14.76 |
Technical Indicators
Market Signals| Indicator | MNOV | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 43.04 | 47.25 |
| Support Level | $1.21 | $9.76 |
| Resistance Level | $1.32 | $11.44 |
| Average True Range (ATR) | 0.05 | 0.44 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 40.00 | 43.17 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.